comparemela.com

Page 2 - Biologic Therapy In Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Updated NCCN Guidelines Now Include Zanubrutinib for WM

The new second-generation BTK inhibitor zanubrutinib is a preferred regimen for the treatment of symptomatic Waldenstrom s macroglobulinemia.

United statesConstantine tamSteven treonInternational workshop on waldenstrom macroglobulinemiaInternational waldenstrom macroglobulinemia foundation educational forumPeter maccallum cancer centreDrug administrationHealth canadaHarvard medical schoolNational comprehensive cancer networkInternational waldenstromMacroglobulinemia foundation educationalMedscape medical newsInternational workshopWaldenstrom hypergammaglobulinemiaAlignant neoplasia

FDA Approves First-Line Pembrolizumab Plus Chemo for Cervical Cancer

The FDA has also approved pembrolizumab alone for patients with recurrent or metastatic cervical cancer.

Raza mirzaDrug administrationEuropean society for medical oncologyCopenhagen university hospitalEuropean societyMedical oncologyCervical cancerAlignant cervix neoplasmMonoclonal antibodyBiologic therapy in cancerIological therapy in cancerIologics cancerUs food and drug administrationNited states food and drug administration

vimarsana © 2020. All Rights Reserved.